BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Daniele Perna(University of Cambridge), David J. Adams(Wellcome Sanger Institute), Florian A. Karreth(Moffitt Cancer Center), Pedro A. Pérez–Mancera(University of Liverpool), Constantine Alifrangis(University College London Hospitals NHS Foundation Trust), Mark J. Arends(Edinburgh Cancer Research), David A. Tuveson(Cold Spring Harbor Laboratory), Marcus Bosenberg(Yale Cancer Center), Francesco Iorio(Human Technopole), Mamunur Rashid(National Institute of Cardiovascular Diseases), Gideon Bollag(Chan Zuckerberg Biohub San Francisco), Alistair G. Rust(Wellcome Sanger Institute)
Cited by 143
Related Papers
Drug repurposing: progress, challenges and recommendations
|Nature Reviews Drug Discovery|2018|4.6k
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
|The Journal of Experimental Medicine|2017|2.4k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k